Low rate of job retention following colorectal cancer diagnosis

December 22, 2015

Nearly half of working individuals with stage III colorectal cancer surveyed did not retain their jobs reportedly due to their cancer diagnosis and treatment, according to a study in the December 22/29 issue of JAMA. Paid sick leave was associated with a greater likelihood of job retention and reduced personal financial burden.

Workers who develop serious illnesses, such as colorectal cancer (CRC), can incur economic hardship, regardless of insurance coverage. Paid sick leave could reduce the need to take unpaid time off during treatment. However, 40 percent of U.S. workers have no paid sick leave. Its provision is not mandated under the Affordable Care Act or the Family Medical Leave Act, nor is it part of health insurance coverage.

Arden M. Morris, M.D., M.P.H., of the University of Michigan, Ann Arbor, and colleagues examined the association between access to paid sick leave and job retention and personal financial burden among patients with CRC. Surveys were mailed to and telephone follow-up conducted with adults with stage III CRC reported to the Surveillance, Epidemiology, and End Results cancer registries of Georgia and metropolitan Detroit between August 2011 and March 2013. Patients were contacted 4 months postoperatively and could respond up to 12 months postoperatively; only those employed at diagnosis were analyzed.

Among 567 employed respondents (68 percent response rate), 56 percent had access to paid sick leave. Fifty-five percent retained their jobs. Others were newly disabled (26 percent), retired (7 percent), or unemployed (8 percent) or had found new jobs (4 percent). Those who retained their jobs were significantly more likely to be men, white, married, without other illness, and were more highly educated and were more likely to have a higher annual income, private health insurance, and access to paid sick leave. Fifty-nine percent of respondents with paid sick leave retained their jobs vs 33 percent without paid sick leave.
(doi:10.1001/jama.2015.12383; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.